# Apollo Commercial Real Estate Finance, Inc. (ARI) — Financial Analysis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-17  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/ari/thesis · /memo/ari

## Financial Snapshot

---
source: coverage-next-full
ticker: ARI
step: 04
title: Financial Quality & Adversarial Sweep
date: 2026-06-16
---

### Step 04 — Financial Quality & Adversarial Sweep: ARI

---

#### 1. Statement Quality Assessment [S1]

##### Key Adjustments: GAAP vs. Distributable Earnings

ARI, like all commercial mortgage REITs, reports both GAAP earnings and "Distributable Earnings" (DE). The critical adjustments:

| GAAP Item | Adjustment to DE | Reason |
|-----------|-----------------|--------|
| General CECL provision (forward-looking) | Add back | Non-cash; management's estimate of future credit losses |
| Realized losses on loan dispositions | Exclude from current period / adjust | One-time charge recognition |
| FX gain/loss on Euro/GBP loans | Exclude | Hedged; non-economic for dollar-denominated equity holders |
| Non-cash compensation (stock-based) | Add back | Non-cash expense |
| Amortization of debt issuance costs | Add back | Non-cash |
| Unrealized gain/loss on derivatives | Exclude | Mark-to-market volatility |

**Primary quality concern:** The distinction between Specific CECL (actual identified credit losses) and General CECL (forward-looking reserve) is critical. In FY2024:
- Specific CECL additions: $149.5M → real credit losses, should be included in normalized earnings
- General CECL releases/additions: smaller, timing-based
- Distributable EPS of $0.43/sh (FY2024) excluded specific CECL → OVERSTATED economic earnings significantly

**Assessment:** GAAP financials are the more conservative and representative basis. Distributable EPS in 2023–2024 was misleading because it excluded specific credit losses that were demonstrably real (Massachusetts Healthcare Loan, multiple European loans resolved at losses). [S1: 10-K FY2024 MD&A]

##### Accounting Quality Flags

| Flag | Status | Detail |
|------|--------|--------|
| Going concern | YES (as of Q1 2026) | Wind-down plan adopted; company no longer a going concern |
| Revenue recognition | Clean | Interest income on accrual basis; appropriate |
| CECL estimation | Inherently judgmental | Elevated sensitivity to macro assumptions; historical estimate vs. actual showed large errors in 2023–2024 |
| Related-party transactions | Elevated | Athene portfolio sale; management fee to Apollo affiliate; requires disclosure quality assessment |
| Consolidation | Standard | No off-balance-sheet vehicles not disclosed |

---

#### 2. Key Financial Metrics Summary [S2]

##### Income Statement (GAAP)

| Metric | FY2022 | FY2023 | FY2024 | FY2025 | Q1 2026 |
|--------|--------|--------|--------|--------|---------|
| Net Interest Income ($M) | $265.6 | $230.7 | $176.1 | $166.7 | ~$36 |
| Provision for Credit Losses ($M) | ~$(12) | ~$(42) | $(155.8) | ~$(40) | N/A |
| Total Revenue (after provision, $M) | ~$254 | ~$110 | ~$(108) | ~$107 | — |
| Net Income/(Loss) ($M) | $253.7 | $109.7 | $(119.6) | $126.7 | ~$30 |
| GAAP EPS (diluted) | $1.64 | $0.72 | $(0.97) | $0.81 | $0.22 |
| Distributable EPS | ~$1.40 | $1.09 | $0.43 | $0.98 | $0.22 |

##### Balance Sheet

| Metric | FY2022 | FY2023 | FY2024 | FY2025 (est) | Q1 2026 |
|--------|--------|--------|--------|--------------|---------|
| Total Assets ($B) | $9.8 | $9.6 | $9.0 | $9.4 | ~$2 (post-sale) |
| Net Loans ($B) | ~$9.1 | ~$8.5 | $7.5 | ~$8.8 | ~$0 |
| Total Debt ($B) | ~$7.8 | ~$7.5 | ~$6.8 | ~$7.4 | ~$0 (repaid) |
| Shareholders' Equity ($B) | ~$2.1 | ~$2.1 | ~$1.7 | ~$1.86 | ~$1.60 |
| Book Value per Share | ~$15.75 | $14.43 | $12.34 | ~$13.37 | ~$12.01 |
| CECL Reserve ($M) | ~$150 | ~$270 | ~$379 | ~$290 | ~$0 (portfolio sold) |
| Leverage (D/E) | ~3.0x | ~3.2x | ~3.2x | ~3.1x | ~0x |

##### Cash Flow (GAAP)

| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|--------|--------|--------|--------|--------|
| Operating Cash Flow ($M) | ~$274 | ~$200 | ~$142 | ~$160 |
| Investing Cash Flow ($M) | ~$(100) | ~$200 | ~$500 | ~$(1,387) |
| Financing Cash Flow ($M) | ~$(200) | ~$(400) | ~$(600) | ~$(700) |
| Dividends Paid ($M) | ~$200 | ~$195 | ~$169 | ~$141 |

*Note: FY2025 investing outflow of -$1.387B reflects portfolio re-build before the Athene sale decision was announced.*

---

#### 3. Adversarial Research Sweep [S3]

*Note: Transcripts not used (coverage-next-full path). Short reports, regulatory actions, and adverse news sourced from web search and filings.*

##### Short/Negative Research
- **Massachusetts Healthcare Loan (2024):** $128.2M realized loss on a single US loan — the largest single realized loss in ARI's history. Borrower defaulted; ARI took ownership of the collateral and sold at a loss. The incident highlighted concentration risk in the senior loan book and the limits of first-mortgage protection when underlying collateral value deteriorated sharply. [S3: 10-K FY2024]
- **European office exposure concerns (2023–2024):** Multiple bearish analyst reports flagged ARI's 33.9% UK exposure as a structural risk during the post-COVID office vacancy surge. Non-accrual loans peaked at $486.8M (Dec 2024), with the bulk European-based. [S3: Analyst notes]
- **Dividend cut (Q3 2024):** ARI cut its quarterly dividend from $0.35 → $0.25 (-28.6%), confirming that distributable earnings of $0.43/sh in FY2024 were insufficient to cover the prior $1.40 annualized payout. Bears argued the cut was overdue and management was slow to act. [S3: 8-K Aug 2024]

##### Governance / Related-Party Concerns
- **Athene transaction:** Bears argued the sale of ARI's portfolio to an Apollo-affiliated buyer at 99.7% of par (not 100%) represented a conflict of interest — Apollo benefits from Athene's balance sheet growing with high-yield CRE assets while ARI shareholders received slightly below par. Management countered that 99.7% of par was fair given credit quality of some loans and the speed/certainty of execution. Special Committee conducted 24 meetings before approving. [S3: DEF 14A 2026]
- **Management fee extraction:** Over ARI's 15-year life, ACREFI collected estimated $400–500M+ in aggregate management fees from ARI shareholders. The company never achieved a P/BV premium to book. Critics argue externally managed mREITs are structurally designed to extract fees over time while book value erodes. [S3: Proxy disclosures, academic research on externally managed REITs]
- **No open-market insider buying:** In 24 months through June 2026, no insider purchased ARI shares in the open market. The CEO sold ~$1.6M of shares in 2025 via 10b5-1 plan. Insiders own only ~0.68% of shares. This lack of alignment is a persistent governance concern. [S3: Form 4 filings]

##### Legal / Regulatory
- No material pending lawsuits identified in SEC filings beyond ordinary-course.
- Foreign corrupt practices act (FCPA) risk: European operations in Spain, Italy, Germany create elevated FCPA/anti-bribery exposure; 10-K discloses standard risk language; no investigations identified.
- OFAC/AML: Standard financial services risk; no adverse disclosures.

##### Overall Adversarial Assessment

| Risk | Severity | Resolution |
|------|----------|------------|
| Massachusetts Healthcare Loan | REALIZED | Fully written off; loss taken |
| European office non-accruals | RESOLVING | $486.8M peak → $301M (Mar 2026) → $0 (Apr 2026 sale) |
| Dividend cut | RESOLVED | Cut made; $3.75/sh special dividend replaces ongoing dividend |
| Athene related-party | DISCLOSED | Special Committee process complete; 99.7% of par accepted |
| External manager fee extraction | STRUCTURAL | Unavoidable in this vehicle design; dissolved by wind-down |
| Insider misalignment | STRUCTURAL | Unchanged; wind-down aligns interests (CEO's RSUs worth more at higher liquidation value) |

**Net adversarial assessment:** The major financial risks are resolved via the portfolio sale. Remaining risk is legal contingencies in the dissolution process, tax matters, and the final management termination fee.

---

#### Source Index

| Citation | Source | Date |
|----------|--------|------|
| [S1] | ARI 10-K FY2024 MD&A — GAAP vs. DE reconciliation | Feb 2025 |
| [S2] | StockAnalysis.com; XBRL summary; 10-K/10-Q filing data | 2026-06-16 |
| [S3] | Web search — short reports, analyst notes, proxy, Form 4 | 2026-06-16 |

---

*Thesis tracker update: Financial quality was lower than distributable earnings suggested (specific CECL excluded). The adversarial sweep validates the wind-down thesis — no undisclosed landmines. Remaining tail risk is dissolution process contingencies, not operating credit risk (portfolio sold).*

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/ARI/fundamental

## Navigation

- Overview: /stocks/ari
- Financials (this page): /stocks/ari/financials
- Thesis: /stocks/ari/thesis
- Investment Memo: /memo/ari
- Coverage universe: /stocks